All In Biotech

Drug Trial Radar · NCT04775485

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Apr 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

141

Planned (sponsor's estimate)

Start

Apr 22, 2021

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Sponsor type
Industry
Collaborators
Pacific Pediatric Neuro-Oncology Consortium
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying genomic alterations will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments (CLIA) of 1988 or other similarly certified laboratories prior to enrollment into any of the arms. The study will consist of a screening period, a treatment period, a long-term extension phase, end of treatment (EOT) visit(s), a safety follow-up visit, and long-term follow-up assessments.

Conditions

  • Low-grade Glioma
  • Advanced Solid Tumor

Interventions

  • TovorafenibDrug

    Tovorafenib is an oral Type II RAF kinase inhibitor available in 100 mg immediate-release tablet or 25 mg/milliliter (mL) powder for reconstitution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Arm 1: Overall response rateTime frame: Up to 48 months
  2. Arm 2: Number of participants reporting adverse eventsTime frame: Up to 48 months
  3. Arm 2: Number of participants with clinically significant changes in clinical chemistry parametersTime frame: Up to 48 months
  4. Arm 2: Number of participants with clinically significant changes in hematology parametersTime frame: Up to 48 months
  5. Arm 3: Overall response rateTime frame: Up to 48 months

Locations

35 sites in 11 countries. Site status is shown where the registry gives one.

  • UCSF Benioff Children's Hospital

    San Francisco, California · Recruiting

  • Children's National Medical Center

    Washington D.C., District of Columbia · Recruiting

  • Lurie Children's Hospital of Chicago

    Chicago, Illinois · Recruiting

  • Johns Hopkins Hospital

    Baltimore, Maryland · Terminated

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • CS Mott Children's Hospital

    Ann Arbor, Michigan · Recruiting

  • St. Louis Children's Hospital

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Duke Cancer Center

    Durham, North Carolina · Recruiting

  • Doernbecher Children's Hospital Oregon & Health Science University

    Portland, Oregon · Terminated

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • University of Utah

    Salt Lake City, Utah · Recruiting

  • Seattle Children's Hospital

    Seattle, Washington · Recruiting

  • Queensland Children's Hospital

    Brisbane, Australia · Recruiting

  • Royal Children's Hospital

    Parkville, Australia · Recruiting

  • Perth Children's Hospital

    Perth, Australia · Recruiting

  • Sydney Children's Hospital

    Randwick, Australia · Recruiting

  • The Children's Hospital at Westmead

    Westmead, Australia · Recruiting

  • Centre Hospitalier Universitaire Ste-Justine

    Montreal, Quebec, Canada · Recruiting

  • Montreal Children's Hospital

    Montreal, Quebec, Canada · Recruiting

  • Centre Mère-Enfant Soleil du CHU

    Québec, Quebec, Canada · Recruiting

  • Rigshospitalet

    Copenhagen, Denmark · Recruiting

  • Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Otto-Heubner-Centrum für Kinder

    Berlin, Germany · Recruiting

  • Hopp-Kindertumorzentrum Heidelberg (KiTZ), KiTZ Clinical Trial Unit (ZIPO)

    Heidelberg, Germany · Recruiting

  • Rambam Health Care Campus

    Haifa, Israel · Recruiting

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel · Recruiting

  • The Chaim Sheba Medical Center

    Ramat Gan, Israel · Recruiting

  • Princess Maxima Center for Pediatric Oncology

    Utrecht, Netherlands · Recruiting

  • KK Women's and Children's Hospital

    Singapore, Singapore · Recruiting

  • Seoul National University Hospital

    Seoul, South Korea · Recruiting

  • Severance Hospital - Yonsei University

    Seoul, South Korea · Recruiting

  • Universitäts-Kinderspital Zürich - Eleonorenstiftung

    Zurich, Switzerland · Recruiting

  • UCL Great Ormond Street Institute of Child Health

    London, United Kingdom · Recruiting

  • Newcastle University

    Newcastle upon Tyne, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.